The Native Antigen Company produces both native and recombinant antigens for a range of established and emerging viral and bacterial diseases, including SARS-CoV-2 (COVID-19).
Our antigens are suitable for use in vaccine R&D, as components for serological based diagnostic assays and for fundamental research into infectious disease.
Our HEK293 mammalian cell expression system is able to introduce proper protein folding and full post-translational modifications, which are essential for full biological and antigenic activity.
Key products
- Proteins and antibodies for COVID-19 research and diagnostics
- Proteins and antibodies for Dengue research and diagnostics
- Reagents for infectious diseases research
Product portfolio
Native and recombinant antigens
- Viral antigens
- Bacterial antigens
- SARS-CoV-2 antigens
- Viral lysates
- Parasite antigens
Antibodies
- Antibodies against infectous disease targets
Viral receptors
- Human ACE2
- Human CD147
- Human DAG
- Human MOG
- Other human receptors
Vaccine sera
- Yellow fever virus pre-vaccination and post-vaccination bleeds
- Japanese encephalitis virus pre-vaccination and post-vaccination bleeds
Other virus research products
- Virus immunoassays
- Metabolic labeling kits (Legio-tag, BacTag)
- Conjugation kits (HRP, Biotin, AP, FITC)
- Blocking buffers
eBooks and catalogs
| Filename | Download |
|---|---|
| Native_Antigen_Company_2021_Product_Catalogue.pdf |  |
| Native_Antigen_Company_Choosing_The_Right_Reagents_for_Your_Coronavirus_Immunoassay.pdf | |
| Native_Antigen_Company_Dengue_eBook.pdf | |
